Filter :
Standard and/or project under the direct responsibility of ISO/TC 212 Secretariat | Stage | ICS |
---|---|---|
Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for saliva — Isolated human DNA |
60.60 | |
Competence requirements for biorisk management advisors |
60.00 | |
Medical laboratories — Concepts and specifications for the design, development, implementation, and use of laboratory-developed tests |
40.60 | |
In vitro diagnostic test systems — Requirements and recommendations for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by nucleic acid amplification methods |
60.60 | |
ISO 35001 — Biorisk management for laboratories and other related organisations — Implementation guidance |
20.00 |
|
Specifications for pre-examination processes for circulating tumor cells (CTCs) in venous whole blood — Part 1: Isolated RNA |
30.99 | |
Specifications for pre-examination processes for circulating tumor cells (CTCs) in venous whole blood — Part 2: Isolated DNA |
30.99 | |
Specifications for pre-examination processes for circulating tumor cells (CTCs) in venous whole blood — Part 3: Preparations for analytical CTC staining |
30.99 | |
Sequencing and clinical application to infectious diseases |
20.00 |
|
Medical laboratories — Particular requirements for quality and competence |
95.99 | |
Medical laboratories — Particular requirements for quality and competence |
95.99 | |
Medical laboratories — Requirements for quality and competence |
95.99 | |
Medical laboratories — Requirements for quality and competence |
60.60 | |
Medical laboratories — Requirements for safety |
95.99 | |
Medical laboratories — Requirements for safety |
60.60 | |
In vitro diagnostic medical devices — Measurement of quantities in samples of biological origin — Presentation of reference measurement procedures |
95.99 | |
In vitro diagnostic medical devices — Measurement of quantities in samples of biological origin — Requirements for content and presentation of reference measurement procedures |
90.92 | |
In vitro diagnostic medical devices — Requirements for reference measurement procedures |
40.60 | |
In vitro diagnostic medical devices — Measurement of quantities in samples of biological origin — Description of reference materials |
95.99 | |
In vitro diagnostic medical devices — Measurement of quantities in samples of biological origin — Requirements for certified reference materials and the content of supporting documentation |
90.92 | |
In vitro diagnostic medical devices — Requirements for certified reference materials and the content of supporting documentation |
40.60 | |
Laboratory medicine — Requirements for reference measurement laboratories |
95.99 | |
Laboratory medicine — Requirements for the competence of calibration laboratories using reference measurement procedures |
90.60 | |
In vitro diagnostic test systems — Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus |
95.99 | |
In vitro diagnostic test systems — Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus |
90.60 | |
Clinical laboratory medicine — In vitro diagnostic medical devices — Validation of user quality control procedures by the manufacturer |
90.60 | |
Clinical laboratory testing and in vitro diagnostic test systems — Reference method for testing the in vitro activity of antimicrobial agents against yeast fungi involved in infectious diseases |
95.99 | |
Clinical laboratory testing and in vitro diagnostic test systems — Broth micro-dilution reference method for testing the in vitro activity of antimicrobial agents against yeast fungi involved in infectious diseases |
60.60 | |
Manufacturers’considerations for in vitro diagnostic medical devices in a public health crisis |
30.60 | |
Clinical laboratory testing — Criteria for acceptable lots of dehydrated Mueller-Hinton agar and broth for antimicrobial susceptibility testing |
90.20 | |
In vitro diagnostic medical devices — Measurement of quantities in biological samples — Metrological traceability of values assigned to calibrators and control materials |
95.99 | |
In vitro diagnostic medical devices — Requirements for establishing metrological traceability of values assigned to calibrators, trueness control materials and human samples |
60.60 | |
Medical laboratories — Reagents for staining biological material — Guidance for users |
90.93 | |
Clinical laboratory testing and in vitro medical devices — Requirements for in vitro monitoring systems for self-testing of oral anticoagulant therapy |
95.99 | |
Clinical laboratory testing and in vitro medical devices — Requirements for in vitro monitoring systems for self-testing of oral anticoagulant therapy |
60.60 | |
In vitro diagnostic test systems — Qualitative nucleic acid-based in vitro examination procedures for detection and identification of microbial pathogens — Part 1: General requirements, terms and definitions |
95.99 | |
In vitro diagnostic test systems — Nucleic acid amplification-based examination procedures for detection and identification of microbial pathogens — Laboratory quality practice guide |
60.60 | |
Clinical laboratory testing and in vitro diagnostic test systems — In vitro diagnostic medical devices for professional use — Summary of regulatory requirements for information supplied by the manufacturer |
95.99 | |
In vitro diagnostic medical devices — Information supplied by the manufacturer (labelling) — Part 1: Terms, definitions and general requirements |
95.99 | |
In vitro diagnostic medical devices — Information supplied by the manufacturer (labelling) — Part 1: Terms, definitions, and general requirements |
60.60 | |
In vitro diagnostic medical devices — Information supplied by the manufacturer (labelling) — Part 2: In vitro diagnostic reagents for professional use |
95.99 | |
In vitro diagnostic medical devices — Information supplied by the manufacturer (labelling) — Part 2: In vitro diagnostic reagents for professional use |
60.60 | |
In vitro diagnostic medical devices — Information supplied by the manufacturer (labelling) — Part 3: In vitro diagnostic instruments for professional use |
95.99 | |
In vitro diagnostic medical devices — Information supplied by the manufacturer (labelling) — Part 3: In vitro diagnostic instruments for professional use |
60.60 | |
In vitro diagnostic medical devices — Information supplied by the manufacturer (labelling) — Part 4: In vitro diagnostic reagents for self-testing |
95.99 | |
In vitro diagnostic medical devices — Information supplied by the manufacturer (labelling) — Part 4: In vitro diagnostic reagents for self-testing |
60.60 | |
In vitro diagnostic medical devices — Information supplied by the manufacturer (labelling) — Part 5: In vitro diagnostic instruments for self-testing |
95.99 | |
In vitro diagnostic medical devices — Information supplied by the manufacturer (labelling) — Part 5: In vitro diagnostic instruments for self-testing |
60.60 | |
In vitro diagnostic medical devices — Measurement of quantities in biological samples — Metrological traceability of values for catalytic concentration of enzymes assigned calibrators and control materials |
90.20 | |
Molecular in vitro diagnostic examinations — Specificationsfor pre-examination processes for human specimens — Isolated microbiome DNA |
20.00 |
|
Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for exosomes and other extracellular vesicles in venous whole blood — DNA, RNA and proteins |
20.00 |
|
Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for venous whole blood — Isolated circulating cell free RNA from plasma |
20.00 |
|
Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for urine and other body fluids — Isolated cell free DNA |
30.60 | |
In vitro diagnostic medical devices — Information supplied by the manufacturer with in vitro diagnostic reagents for staining in biology |
95.99 | |
In vitro diagnostic medical devices — Information supplied by the manufacturer with in vitro diagnostic reagents for staining in biology |
90.93 | |
Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for formalin-fixed and paraffin-embedded (FFPE) tissue — Part 1: Isolated RNA |
90.60 | |
Molecular in vitro diagnostic examinations — Specifications for pre-examinations processes for formalin-fixed and paraffin-embedded (FFPE) tissue — Part 2: Isolated proteins |
90.60 | |
Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for formalin-fixed and paraffin-embedded (FFPE) tissue — Part 3: Isolated DNA |
90.60 | |
Molecular in vitro diagnostic examinations — Specifications for preexamination processes for formalin-fixed and paraffin-embedded (FFPE) tissue — Part 4: In situ detection techniques |
60.60 | |
Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for frozen tissue — Part 1: Isolated RNA |
90.60 | |
Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for frozen tissue — Part 2: Isolated proteins |
90.60 | |
Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for frozen tissue — Part 3: Isolated DNA |
60.60 | |
Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for venous whole blood — Part 1: Isolated cellular RNA |
90.20 | |
Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for venous whole blood — Part 2: Isolated genomic DNA |
90.20 | |
Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for venous whole blood — Part 3: Isolated circulating cell free DNA from plasma |
60.60 | |
Requirements for the collection and transport of samples for medical laboratory examinations |
60.60 | |
Medical laboratories — Requirements for collection, transport, receipt, and handling of samples |
95.99 | |
Clinical laboratory testing and in vitro diagnostic test systems — Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices — Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases |
95.99 | |
Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices — Part 1: Broth micro-dilution reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases |
90.20 | |
Clinical laboratory testing and in vitro diagnostic test systems — Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices — Part 2: Evaluation of performance of antimicrobial susceptibility test devices |
95.99 | |
Clinical laboratory testing and in vitro diagnostic test systems — Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices — Part 2: Evaluation of performance of antimicrobial susceptibility test devices against reference broth micro-dilution |
60.60 | |
Medical laboratories — Practical guidance for the estimation of measurement uncertainty |
90.93 | |
In vitro diagnostic medical devices — Clinical performance studies using specimens from human subjects — Good study practice |
90.20 | |
In vitro diagnostic medical devices — Requirements for international harmonisation protocols establishing metrological traceability of values assigned to calibrators and human samples |
60.60 | |
In vitro diagnostic medical devices — Multiplex molecular testing for nucleic acids — Part 1: Terminology and general requirements for nucleic acid quality evaluation |
60.60 | |
In vitro diagnostic medical devices — Multiplex molecular testing for nucleic acids — Part 2: Validation and verification |
60.60 | |
In vitro diagnostic medical devices — Multiplex molecular testing for nucleic acids — Part 3: Interpretation and reports |
40.99 | |
Medical laboratories — Application of risk management to medical laboratories |
90.92 | |
Medical laboratories — Reduction of error through risk management and continual improvement |
95.99 | |
Medical laboratories — Reduction of error through risk management and continual improvement — Technical Corrigendum 1 |
95.99 | |
Medical laboratories — Application of risk management to medical laboratories |
20.00 |
|
Guidance for supervisors and operators of point-of-care testing (POCT) devices |
90.92 | |
Requirements and recommendations for supervisors and operators of point-of-care testing (POCT) equipment |
60.00 | |
Medical laboratories — Guidance on laboratory implementation of ISO 15189: 2003 |
95.99 | |
Point-of-care testing (POCT) — Requirements for quality and competence |
95.99 | |
Point-of-care testing (POCT) — Requirements for quality and competence |
95.99 | |
Molecular in vitro diagnostic examinations — Specifications for pre-examination processes in metabolomics in urine, venous blood serum and plasma |
60.60 | |
Basic semen examination — Specification and test methods |
60.60 | |
In vitro diagnostic medical devices — Evaluation of stability of in vitro diagnostic reagents |
90.92 | |
In vitro diagnostic medical devices — Evaluation of stability of in vitro diagnostic reagents |
20.00 |
|
Medical laboratories — Guidance on application of ISO 15189 in anatomic pathology |
60.00 | |
Medical laboratories — Part 1: General principles for the application of artificial intelligence in medical laboratories |
20.00 |
|
Medical laboratories — Part 2: Digital pathology and artificial intelligence (AI)-based image analysis |
20.00 |
|
Lateral flow immunoassay for rapid diagnostic testing — General guideline for test performance |
20.00 |
|
Electronic Instructions for Use for In Vitro Diagnostic Medical Devices (Minimum required information and means of delivery) |
20.00 |
|
Biorisk management for laboratories and other related organisations |
60.60 | |
Biorisk management for laboratories and other related organisations — Amendment 1: Climate action changes |
60.60 |
No matching records found. Please try changing the filter settings.